Iva Toudjarska
Founder & Chief Executive Office Zeal Therapeutics
Seminars
Thursday 16th October 2025
Roundtable Discussion: Models & Assays for PKD: Organoids, Rodents, EV-Based Diagnostics, and AI Tools
10:50 am
- Using human kidney organoids and zebrafish or C. elegans models for early screening of therapeutic targets and cystogenesis assays
- Developing EV-based urine assays to detect polycystin-1/2 levels and prognosticate disease before significant cyst development
- Applying AI-enabled imaging tools and organoid video analysis platforms (e.g. “Organoid Tracker”) to quantify cyst formation rate, growth velocity, morphology
- Standardizing rodent PKD model cores (e.g. varying progression rates) to allow cross-study comparability and better translational predictivity
Monday 16th March 2026
Roundtable Discussion: Data, Standards & Infrastructure to Accelerate PKD Research: What Does the Field Actually Need Next?
1:00 pm
- Barriers to data sharing, standardization, and interoperability across PKD studies
- What “good” looks like for harmonised imaging, biomarker, and clinical datasets
- Opportunities for pre‑competitive consortia to build shared resources (models, registries, repositories)
- What infrastructure gaps most slow down target validation, trial design, and regulatory engagement
Wednesday 18th March 2026
Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?
10:30 am
- Balancing innovation with clinical feasibility and scalable development in kidney disease
- Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
- Exploring whether targeted delivery strategies must be disease-specific to maximize impact
- Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown
Monday 16th March 2026
Chair’s Closing Remarks
3:55 pm
Thursday 16th October 2025
Chair’s Opening Remarks & Audience Welcome
9:00 am
